Aquestive Therapeutics (NASDAQ:AQST) COO Cassie Jung Sells 67,575 Shares

Key Points

• Cassie Jung, COO of Aquestive Therapeutics, sold 67,575 shares of the company's stock for approximately $473,700, representing a 21.92% decrease in her position.
• Shares of Aquestive Therapeutics rose by 1% to $7.08, with trading volume exceeding its average at 3.3 million shares.
• Analysts have varying ratings for the stock; JMP Securities raised their price target to $12.00, while others have issued ratings ranging from "sell" to "strong-buy."

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) COO Cassie Jung sold 67,575 shares of Aquestive Therapeutics stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $7.01, for a total transaction of $473,700.75. Following the completion of the sale, the chief operating officer owned 240,771 shares in the company, valued at approximately $1,687,804.71. This trade represents a 21.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Cassie Jung also recently made the following trade(s):

• On Thursday, September 4th, Cassie Jung sold 62,180 shares of Aquestive Therapeutics stock. The shares were sold at an average price of $5.00, for a total transaction of $310,900.00.

Aquestive Therapeutics Stock Up 1.0%

Shares of NASDAQ AQST traded up $0.07 during trading on Friday, hitting $7.08. The company had a trading volume of 3,309,585 shares, compared to its average volume of 1,911,560. The stock has a fifty day simple moving average of $5.00 and a two-hundred day simple moving average of $3.81. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.12 and a fifty-two week high of $7.51. The firm has a market capitalization of $706.02 million, a price-to-earnings ratio of -10.11 and a beta of 1.77.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.04. The company had revenue of $10.00 million during the quarter, compared to analyst estimates of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. On average, analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on AQST shares. JMP Securities boosted their price target on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the stock a "market outperform" rating in a research report on Thursday, October 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Aquestive Therapeutics in a research report on Wednesday, October 8th. Lifesci Capital upgraded shares of Aquestive Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 3rd. Zacks Research upgraded shares of Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 13th. Finally, Oppenheimer boosted their price target on shares of Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an "outperform" rating in a research report on Monday, September 8th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $10.71.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in AQST. Summit Wealth & Retirement Planning Inc. purchased a new stake in shares of Aquestive Therapeutics in the 1st quarter valued at approximately $29,000. Victory Capital Management Inc. purchased a new stake in shares of Aquestive Therapeutics in the 1st quarter valued at approximately $31,000. BNP Paribas Financial Markets raised its stake in shares of Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock valued at $31,000 after acquiring an additional 4,134 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Aquestive Therapeutics in the 1st quarter valued at approximately $33,000. Finally, USAdvisors Wealth Management LLC purchased a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at approximately $33,000. 32.45% of the stock is owned by hedge funds and other institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.